Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15022
UPID:
SUZ12_HUMAN
Alternative names:
Chromatin precipitated E2F target 9 protein; Joined to JAZF1 protein; Suppressor of zeste 12 protein homolog
Alternative UPACC:
Q15022; Q96BD9
Background:
Polycomb protein SUZ12, known as Chromatin precipitated E2F target 9 protein, Joined to JAZF1 protein, and Suppressor of zeste 12 protein homolog, plays a pivotal role in gene silencing. As a core component of the PRC2 complex, it methylates histone H3 on Lys-9 and Lys-27, leading to transcriptional repression of genes like HOXC8, HOXA9, MYT1, and CDKN2A.
Therapeutic significance:
The involvement of SUZ12 in Imagawa-Matsumoto syndrome, characterized by overgrowth, dysmorphic features, and intellectual disability, underscores its potential as a target for therapeutic intervention. Understanding the role of Polycomb protein SUZ12 could open doors to potential therapeutic strategies.